RxSight (RXST) Stock Analysis & Winston Score

RxSight is a medical device company that makes a special type of artificial lens for people who need cataract surgery. Its main product is the Light Adjustable Lens (LAL), which is unique because doctors can fine-tune a patient's vision *after* the surgery using ultraviolet light treatments. This makes it the only FDA-approved intraocular lens that can be adjusted post-implantation, giving it a distinct position in the U.S. eye care market. The company sells its lenses and the special light delivery devices to ophthalmologists and eye surgery centers, primarily in the United States. With a gross margin above 77%, the underlying product economics are strong, but heavy spending on sales, marketing, and R&D means the company is still losing money overall. RxSight's key growth driver is expanding the number of doctors and clinics adopting the LAL system, though its small size and ongoing losses make it vulnerable if adoption grows more slowly than expected.